{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "From Reversal to Rehearing: USPTO to Revisit Decision Limiting Obviousness-Type Double Patenting Rejections",
    "url": "https://www.lexblog.com/2026/03/13/from-reversal-to-rehearing-uspto-to-revisit-decision-limiting-obviousness-type-double-patenting-rejections/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-FKSS0KJD",
        "url": "https://www.lexblog.com/lib/FKSS0KJD/"
    },
    "datePublished": "2026-03-13T16:24:51-04:00",
    "dateModified": "2026-03-13T16:25:20-04:00",
    "author": {
        "@type": "Person",
        "name": "Rolando Rengifo, Aydin H. Harston"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Rothwell Figg"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Biosimilars Law Bulletin",
    "about": "Intellectual Property",
    "sourceUrl": "https://www.biosimilarsip.com/?p=5866",
    "sourceStability": "may-move"
}